1.Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder.
Jian-quan HOU ; Jun HE ; Duan-gai WEN ; Zi-xing CHEN ; Jian ZENG
Chinese Medical Journal 2006;119(13):1118-1120
Aged
;
Aged, 80 and over
;
Biomarkers, Tumor
;
urine
;
Carcinoma, Transitional Cell
;
urine
;
Female
;
Humans
;
Inhibitor of Apoptosis Proteins
;
Male
;
Microtubule-Associated Proteins
;
genetics
;
Middle Aged
;
Neoplasm Proteins
;
genetics
;
RNA, Messenger
;
urine
;
Reverse Transcriptase Polymerase Chain Reaction
;
Urinary Bladder Neoplasms
;
urine
2.Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Chunri YAN ; Ye Hwan KIM ; Ho Won KANG ; Sung Phil SEO ; Pildu JEONG ; Il Seok LEE ; Dongho KIM ; Jung Min KIM ; Yung Hyun CHOI ; Sung Kwon MOON ; Seok Joong YUN ; Wun Jae KIM
Journal of Korean Medical Science 2015;30(12):1784-1792
The potential use of urinary nucleic acids as diagnostic markers in prostate cancer (PCa) was evaluated. Ninety-five urine samples and 234 prostate tissue samples from patients with PCa and benign prostatic hyperplasia (BPH) were analyzed. Micro-array analysis was used to identify candidate genes, which were verified by the two-gene expression ratio and validated in tissue mRNA and urinary nucleic acid cohorts. Real-time quantitative polymerase chain reaction (qPCR) was used to measure urinary nucleic acid levels and tissue mRNA expression. The TSPAN13-to-S100A9 ratio was selected to determine the diagnostic value of urinary nucleic acids in PCa (P = 0.037) and shown to be significantly higher in PCa than in BPH in the mRNA and nucleic acid cohort analyses (P < 0.001 and P = 0.013, respectively). Receiver operating characteristic (ROC) analysis showed that the area under the ROC curve was 0.898 and 0.676 in tissue mRNA cohort and urinary nucleic acid cohort, respectively. The TSPAN13-to-S100A9 ratio showed a strong potential as a diagnostic marker for PCa. The present results suggest that the analysis of urine supernatant can be used as a simple diagnostic method for PCa that can be adapted to the clinical setting in the future.
Aged
;
Aged, 80 and over
;
Biomarkers, Tumor/*genetics/*urine
;
Calgranulin B/*genetics
;
Cohort Studies
;
Humans
;
Male
;
Middle Aged
;
Nucleic Acids/*genetics/*urine
;
Oligonucleotide Array Sequence Analysis
;
Prostate/metabolism
;
Prostatic Hyperplasia/diagnosis/genetics/urine
;
Prostatic Neoplasms/diagnosis/*genetics/*urine
;
RNA, Messenger/genetics/metabolism
;
RNA, Neoplasm/genetics/metabolism
;
ROC Curve
;
Real-Time Polymerase Chain Reaction
;
Tetraspanins/*genetics
3.Molecular markers in prostate cancer. Part I: predicting lethality.
Sachin AGRAWAL ; William D DUNSMUIR
Asian Journal of Andrology 2009;11(1):14-21
Assessing the lethality of 'early,' potentially organ-confined prostate cancer (PCa) is one of the central controversies in modern-day urological clinical practice. Such cases are often considered for radical 'curative' treatment, although active surveillance may be equally appropriate for many men. Moreover, the balance between judicious intervention and overtreatment can be difficult to judge. The patient's age, comorbidities, family history and philosophy of self-health care can be weighed against clinical features such as the palpability of disease, the number and percentage of biopsy cores involved with the disease, histological grade, presenting prostate-specific antigen (PSA) and possible previous PSA kinetics. For many years, scientists and physicians have sought additional molecular factors that may be predictive for disease stage, progression and lethality. Usually, claims for a 'new' unique marker fall short of true clinical value. More often than not, such molecular markers are useful only in multivariate models. This review summarizes relevant molecular markers and models reported up to and including 2008.
Antigens, Neoplasm
;
urine
;
Biomarkers, Tumor
;
genetics
;
metabolism
;
Humans
;
Male
;
Predictive Value of Tests
;
Prognosis
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms
;
diagnosis
;
metabolism
;
mortality
;
Sensitivity and Specificity